ANI PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ANIP)

Historical Holders from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
ANIP on Nasdaq
Shares outstanding
22,278,088
Price per share
$78.94
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
20,389,327
Total reported value
$1,867,651,891
% of total 13F portfolios
0%
Share change
+484,082
Value change
+$52,979,817
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
265
Price from insider filings
$82.40
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ANI PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ANIP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 11% $230,596,038 2,517,424 BlackRock, Inc. 30 Sep 2025
Meridian Venture Partners II GP, L.P. 4.8% -12% $95,056,292 -$13,782,000 1,034,570 -13% Robert E. Brown, Jr. 21 Aug 2025
MILLENNIUM MANAGEMENT LLC 3.8% -28% $51,596,400 -$17,191,339 818,341 -25% Millennium Management LLC 31 Mar 2025
INTEGRATED CORE STRATEGIES (US) LLC 0.3% -98% $5,976,442 -$96,309,614 65,245 -94% Millennium Management LLC 30 Sep 2025
As of 30 Sep 2025, ANI PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ANIP) has 265 institutional shareholders filing 13F forms. They hold 20,389,327 shares. of 22,278,088 outstanding shares (92%) .

Top 25 institutional shareholders own 57% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 2,548,892 -1.2% 0% $233,478,507
VANGUARD GROUP INC 5.7% 1,277,470 +0.01% 0% $117,016,252
STATE STREET CORP 3.2% 711,708 -0.62% 0% $65,192,453
Global Alpha Capital Management Ltd. 2.8% 630,590 -27% 3.3% $57,762,044
UBS Group AG 2.6% 589,874 +46% 0.01% $54,032,458
CITADEL ADVISORS LLC 2.6% 580,085 +1.8% 0.04% $53,135,786
DIMENSIONAL FUND ADVISORS LP 2.3% 505,428 -8.7% 0.01% $46,297,714
GEODE CAPITAL MANAGEMENT, LLC 2.1% 458,014 +7.1% 0% $41,959,481
Deep Track Capital, LP 2% 450,000 -36% 1.2% $41,220,000
Point72 Asset Management, L.P. 1.8% 399,092 0.08% $36,556,814
Nuveen, LLC 1.8% 395,075 +6.5% 0.01% $36,188,870
GOLDMAN SACHS GROUP INC 1.7% 379,026 +84% 0.01% $34,718,781
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.6% 360,178 0.02% $32,992,305
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 1.6% 348,680 -29% 0.08% $31,939,088
Rubric Capital Management LP 1.5% 343,414 +33% 0.42% $31,456,722
Soleus Capital Management, L.P. 1.5% 340,243 +571% 1.7% $31,166,259
TANG CAPITAL MANAGEMENT LLC 1.4% 317,500 0% 1.1% $29,083,000
AMERIPRISE FINANCIAL INC 1.3% 291,841 -24% 0.01% $26,732,635
MACQUARIE GROUP LTD 1.3% 291,129 -31% 0.03% $26,667,000
Balyasny Asset Management L.P. 1.3% 286,149 +2786% 0.05% $26,211,248
RENAISSANCE TECHNOLOGIES LLC 1.2% 272,902 +113% 0.03% $24,997,823
Ranger Investment Management, L.P. 1.2% 271,345 -49% 1.7% $24,855,202
Aberdeen Group plc 1.2% 269,678 -26% 0.04% $24,702,504
DEUTSCHE BANK AG\ 1.1% 252,568 +14% 0.01% $23,135,229
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.1% 235,661 -8.5% 0% $21,586,548

Institutional Holders of ANI PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ANIP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 210,799 $16,640,945 +$10,833,046 7,894.01% 6
2025 Q3 20,389,327 $1,867,651,891 +$52,979,817 9,160% 265
2025 Q2 19,740,780 $1,287,101,463 -$20,859,394 6,525% 230
2025 Q1 19,935,951 $1,334,727,241 +$48,407,066 6,695% 225
2024 Q4 19,278,261 $1,065,655,413 +$20,351,531 5,528% 204
2024 Q3 18,878,833 $1,126,182,016 +$220,505,249 5,966% 207
2024 Q2 15,123,647 $963,078,529 +$64,704,745 6,368% 200
2024 Q1 14,090,461 $974,035,743 +$35,910,273 6,913% 195
2023 Q4 5,771 $318,213 -$1,243,658 5,514% 1
2023 Q3 13,178,509 $765,151,418 +$50,053,197 5,806% 183
2023 Q2 12,281,745 $661,113,412 +$105,431,066 5,383% 167
2023 Q1 10,347,461 $410,990,262 +$7,051,582 3,972% 136
2022 Q4 10,249,335 $412,408,848 +$3,076,290 4,023% 124
2022 Q3 10,251,468 $329,681,198 +$12,812,671 3,213.98% 114
2022 Q2 9,849,174 $292,509,926 +$29,898,898 2,966.82% 107
2022 Q1 9,165,070 $257,700,283 -$5,702,648 2,811% 112
2021 Q4 8,883,250 $409,254,517 +$81,857,541 4,608% 121
2021 Q3 7,274,171 $238,621,888 +$15,298,835 3,282% 106
2021 Q2 7,210,959 $252,642,638 -$2,822,454 3,504.75% 107
2021 Q1 7,289,145 $263,342,493 -$827,893 3,613.94% 101
2020 Q4 7,313,833 $212,427,867 +$2,525,200 2,904% 107
2020 Q3 7,258,028 $204,754,743 -$7,680,260 2,821% 102
2020 Q2 7,265,803 $234,859,257 -$25,693,214 3,233.9% 118
2020 Q1 7,937,890 $323,351,243 -$12,411,394 4,073.97% 133
2019 Q4 8,074,378 $497,852,188 -$71,007,457 6,166.86% 160
2019 Q3 9,099,403 $663,043,236 +$37,888,167 7,287.8% 179
2019 Q2 8,559,521 $703,729,040 +$78,918,314 8,220% 188
2019 Q1 7,474,791 $527,055,463 +$37,891,180 7,054.01% 180
2018 Q4 7,079,072 $318,706,901 -$17,756,503 4,501.99% 155
2018 Q3 7,460,823 $421,705,111 +$13,575,213 5,653.99% 162
2018 Q2 7,183,872 $479,918,569 +$20,953,935 6,679.89% 177
2018 Q1 6,621,431 $385,550,004 +$5,067,842 5,822.28% 165
2017 Q4 6,543,592 $421,867,419 +$7,866,332 6,444.83% 151
2017 Q3 6,385,452 $335,102,028 -$1,908,832 5,248.84% 133
2017 Q2 6,421,616 $301,509,484 +$684,666 4,679.6% 141
2017 Q1 6,444,373 $319,070,032 +$59,776,856 4,950.94% 149
2016 Q4 6,237,429 $378,310,629 +$11,094,904 6,061.88% 147
2016 Q3 5,975,556 $396,513,646 +$26,653,651 6,635% 162
2016 Q2 5,598,057 $312,472,690 +$11,598,220 5,581.91% 133
2016 Q1 5,797,200 $195,091,743 -$21,532,977 3,365.82% 114
2015 Q4 6,319,783 $285,412,733 -$30,450,968 4,512.34% 119
2015 Q3 6,966,028 $275,308,091 +$16,574,410 3,950.93% 118
2015 Q2 6,390,277 $396,058,646 -$29,850,393 6,204.84% 118
2015 Q1 6,959,392 $434,650,108 +$84,590,577 6,254.92% 127
2014 Q4 5,627,718 $317,206,714 +$99,161,298 5,638.98% 99
2014 Q3 4,525,202 $128,520,656 -$3,212,791 2,828% 69
2014 Q2 4,487,871 $154,563,359 +$28,391,667 3,443.94% 78
2014 Q1 3,764,373 $118,010,408 +$77,601,492 3,135.06% 64